Clinical trials: Bone Tumor
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination…
- Trial name
- NCT02909972
- Testing
- ALRN-6924, ALRN-6924 in combination with cytarabine
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Aileron Therapeutics, Inc.
Chronic Leukemia, Acute Leukemia
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
In this study, patients will receive a myeloablative preparative regimen consisting of fludarabine and total body irradiation (TBI), followed by a T cell replete, mobilized peripheral blood stem cell (PBSC) allograft from a…
- Conditions
- Chronic Leukemia, Acute Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT01336712
- Testing
- Peripheral Blood Stem Cell Transplant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northside Hospital, Inc.
Osteosarcoma, Paget's Disease
Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
The objective of these studies is to use changes in 3 Tesla MRI measurements of tumor protein content, cell density, and microvessel perfusion, obtained before and after a single cycle of NAC, to predict eventual tumor response…
- Conditions
- Osteosarcoma, Paget's Disease, Ewing Sarcoma
- Trial name
- NCT01882231
- Testing
- DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Bone Cancer
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
- Trial name
- NCT02880319
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Stereotactic Linear Accelerator
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Myelodysplastic Syndromes
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes
RATIONALE: Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00641030
- Testing
- clofarabine, melphalan, gene expression analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Neurofibromatoses
The Neurofibromatosis-associated Tumor Biobank
Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research
- Trial name
- NCT03359304
- Volunteers
- 300 people
- Sponsor
- Ren tingting
Malignant Neoplasm, Metastatic Malignant Neoplasm to the Bone
Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer
This clinical trial studies dual energy computed tomography (CT) in finding cancer that has spread from the original (primary) tumor to the bone (bone metastases) in patients with cancer.
- Trial name
- NCT02354326
- Testing
- virtual non-calcium dual-energy computed tomography, computed tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoid Tumor, Acromegaly
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
- Trial name
- NCT00446082
- Testing
- Pasireotide
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
- Conditions
- Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission
- Trial name
- TOKIN (NCT04626024)
- Testing
- Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal, Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Bone Cancer
Osteosarcoma Maintenance Therapy With OST31-164
Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled.
- Trial name
- OST-164-01 (NCT04974008)
- Testing
- OST31-164
- Where
- 21 sites in United States
- Volunteers
- 39 people
- Sponsor
- Emerald Clinical Inc.
Leukemia, Myelodysplastic Syndrome
PR1 Vaccination in Myelodysplastic Syndrome (MDS)
Primary aim: 1. To determine the immunologic response, using a PR1-HLA-A2 tetramer assay, to 4 subcutaneous (SQ) injections of TVC-PR1 vaccine formulated in Montanide ISA 51 VG followed by granulocyte macrophage…
- Trial name
- NCT00893997
- Testing
- PR-1 vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Acute Disease
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
- Conditions
- Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia
- Trial name
- NCT00607997
- Testing
- vosaroxin
- Where
- 20 sites in United States
- Volunteers
- 113 people
- Sponsor
- Sunesis Pharmaceuticals
Soft Tissue Neoplasms, Bone Neoplasms
Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt
The aim of this study is to identify demographic \& disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) \& treatment outcomes in these patients.
- Conditions
- Soft Tissue Neoplasms, Bone Neoplasms, Neoplasms
- Trial name
- NCT04300179
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Assiut University
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03630991
- Testing
- Edetate Calcium Disodium, Multivitamin, Succimer
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
The main goal of the study is the assessment of duration of major molecular response (MMR) or better at 12 and 36 months after stopping tyrosine kinase inhibitors (TKI) therapy a second or third time in patients with at least…
- Trial name
- NAUT (NCT02917720)
- Testing
- TKI discontinuation, nilotinib
- Where
- 15 sites in Germany, Netherlands
- Volunteers
- 75 people
- Sponsor
- European LeukemiaNet
Osteosarcoma
Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial
The aim of this study is to evaluate the efficacy and safety of pre-operative concurrent Stereotactic Body Radiotherapy (SBRT) and and programmed cell death protein-1 (PD-1) blockade immunotherapy followed by surgical…
- Trial name
- PROMIS (NCT06114225)
- Testing
- metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Ruijin Hospital
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as busulfan and fludarabine phosphate, before a peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01118013
- Testing
- anti-thymocyte globulin, donor lymphocytes, filgrastim
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myeloid Leukemia
Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response
Multi-Center, national, non-drug, prospective cohort study Target patient number is 100 The amount of CD45+/CD34+/CD38-/CD26+ levels of chronic myeloid leukemia (CML) stem cells in CML patients with and without BCR-ABL…
- Trial name
- NCT04104035
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Ankara University
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more…
- Conditions
- Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003960
- Testing
- busulfan, cyclophosphamide, methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myelodysplasia
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC)…
- Conditions
- Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT07249346
- Testing
- Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Hannah Choe, MD